News for Boston Scientific Corporation (BSX-PA)

Boston Scientific Corporation (NYSE:BSX) is one of the top low volatility healthcare stocks to buy now.

We recently published 9 Stocks Jim Cramer Discussed As He Commented On Big Tech. Boston Scientific Corporation (NYSE:BSX) is one of the stocks Jim Cramer recently discussed. Boston Scientific Corporation (NYSE:BSX) is one of the biggest medical device companies in the world. Its shares have gained 18.9% year to date, with July proving to be […]

Boston Scientific Corporation (NYSE:BSX) Q2 2025 Earnings Conference Call July 23, 2025 8:00 AM ETCompany ParticipantsJonathan R.

Boston Scientific Corporation (BSX) has updated its financial projections for the fiscal year 2025, predicting net sales growth of between 18% and 19% compared

PR NewswireMARLBOROUGH, Mass., July 23, 2025 MARLBOROUGH, Mass., July 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sale

Baron Health Care Fund declined for the quarter but outperformed its benchmark, the Russell 3000 Health Care Index. Read more here.

U.S. stock futures are higher after a rally on trade deals, but some megacap tech companies are due to report quarterly results and could swing sentiment.

Market Analysis by covering: Chevron Corp, Citigroup Inc, Intel Corporation, Walt Disney Company. Read 's Market Analysis on Investing.com

Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

Boston Scientific Corporation (NYSE:BSX) is one of Goldman Sachs’ top healthcare stock picks. On July 7, Boston Scientific (NYSE:BSX) saw its shares rise as TD Cowen reaffirmed its Buy rating and $115 price target following FDA approval to expand the use of its Farapulse system for treating persistent atrial fibrillation (AFib). Previously approved for paroxysmal […]

Boston Scientific Corporation (NYSE:BSX) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 7, Boston Scientific Corporation (NYSE:BSX) announced that it has obtained approval to expand the instructions for use (IFU) labeling for the FARAPULSE Pulsed Field Ablation (PFA) System from the US Food and Drug Administration (FDA). The […]

The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Delray Beach, FL, July 09, 2025 (GLOBE NEWSWIRE) -- The global enteral feeding devices market, valued at US$2,807.9 million in 2024, stood at US$2,965.1 million in 2025 and is projected to advance at a resilient CAGR of 6.0% from 2025 to 2030, culminating in a forecasted valuation of US$3,994.2 million by the end of the period. Market growth can be attributed to the rise in the geriatric population, technological advancements, regulatory support, improved awareness of nutritional needs, and the expansion of emerging economies. Innovations in materials, design, and digital integration, along with mechanical advancements, significantly enhance the functionality and safety of enteral feeding systems. The introduction of advanced pump technology, anti-clogging mechanisms, and real-time monitoring systems can further improve patient outcomes and provide caregivers with greater efficiency in managing such cases.

Boston Scientific's Farapulse System secures FDA approval for expanded atrial fibrillation treatment. Analysts project a potential 13.84% upside in stoc

Boston Scientific is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings growth.

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to buy. On June 10, the company announced that it is selling one suburban Twin Cities property and expanding another, mirroring a pattern of companies centralizing in fewer but more dynamic sites. BSX has placed its 226,000 square foot Minnetonka campus on the market, indicating […]

We believe that at its current valuation, Boston Scientific seems relatively overpriced, especially when compared to the broader market and its historical...